242 related articles for article (PubMed ID: 31842393)
21. Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).
Finkel RS
J Child Neurol; 2010 Sep; 25(9):1158-64. PubMed ID: 20519671
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the ternary Usher syndrome SANS/ush2a/whirlin protein complex.
Sorusch N; Bauß K; Plutniok J; Samanta A; Knapp B; Nagel-Wolfrum K; Wolfrum U
Hum Mol Genet; 2017 Mar; 26(6):1157-1172. PubMed ID: 28137943
[TBL] [Abstract][Full Text] [Related]
23. Successful large gene augmentation of USH2A with non-viral episomal vectors.
Toms M; Toualbi L; Almeida PV; Harbottle R; Moosajee M
Mol Ther; 2023 Sep; 31(9):2755-2766. PubMed ID: 37337429
[TBL] [Abstract][Full Text] [Related]
24. Nonsense codons suppression. An acute toxicity study of three optimized TRIDs in murine model, safety and tolerability evaluation.
Corrao F; Zizzo MG; Tutone M; Melfi R; Fiduccia I; Carollo PS; Leonardo AD; Caldara G; Perriera R; Pace A; Belmonte B; Sammataro S; Pibiri I; Lentini L
Biomed Pharmacother; 2022 Dec; 156():113886. PubMed ID: 36265311
[TBL] [Abstract][Full Text] [Related]
25. Novel Usher syndrome pathogenic variants identified in cases with hearing and vision loss.
Pater JA; Green J; O'Rielly DD; Griffin A; Squires J; Burt T; Fernandez S; Fernandez B; Houston J; Zhou J; Roslin NM; Young TL
BMC Med Genet; 2019 May; 20(1):68. PubMed ID: 31046701
[TBL] [Abstract][Full Text] [Related]
26. Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs).
Nagel-Wolfrum K; Möller F; Penner I; Baasov T; Wolfrum U
BioDrugs; 2016 Apr; 30(2):49-74. PubMed ID: 26886021
[TBL] [Abstract][Full Text] [Related]
27. Molecular basis of human Usher syndrome: deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease.
Reiners J; Nagel-Wolfrum K; Jürgens K; Märker T; Wolfrum U
Exp Eye Res; 2006 Jul; 83(1):97-119. PubMed ID: 16545802
[TBL] [Abstract][Full Text] [Related]
28. Four USH2A founder mutations underlie the majority of Usher syndrome type 2 cases among non-Ashkenazi Jews.
Auslender N; Bandah D; Rizel L; Behar DM; Shohat M; Banin E; Allon-Shalev S; Sharony R; Sharon D; Ben-Yosef T
Genet Test; 2008 Jun; 12(2):289-94. PubMed ID: 18452394
[TBL] [Abstract][Full Text] [Related]
29. Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development.
Li S; Li J; Shi W; Nie Z; Zhang S; Ma F; Hu J; Chen J; Li P; Xie X
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371567
[TBL] [Abstract][Full Text] [Related]
30. Usherin defects lead to early-onset retinal dysfunction in zebrafish.
Dona M; Slijkerman R; Lerner K; Broekman S; Wegner J; Howat T; Peters T; Hetterschijt L; Boon N; de Vrieze E; Sorusch N; Wolfrum U; Kremer H; Neuhauss S; Zang J; Kamermans M; Westerfield M; Phillips J; van Wijk E
Exp Eye Res; 2018 Aug; 173():148-159. PubMed ID: 29777677
[TBL] [Abstract][Full Text] [Related]
31. Functional rescue of REP1 following treatment with PTC124 and novel derivative PTC-414 in human choroideremia fibroblasts and the nonsense-mediated zebrafish model.
Moosajee M; Tracey-White D; Smart M; Weetall M; Torriano S; Kalatzis V; da Cruz L; Coffey P; Webster AR; Welch E
Hum Mol Genet; 2016 Aug; 25(16):3416-3431. PubMed ID: 27329764
[TBL] [Abstract][Full Text] [Related]
32. A homozygous nonsense CEP250 mutation combined with a heterozygous nonsense C2orf71 mutation is associated with atypical Usher syndrome.
Khateb S; Zelinger L; Mizrahi-Meissonnier L; Ayuso C; Koenekoop RK; Laxer U; Gross M; Banin E; Sharon D
J Med Genet; 2014 Jul; 51(7):460-9. PubMed ID: 24780881
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives.
Pibiri I; Lentini L; Melfi R; Gallucci G; Pace A; Spinello A; Barone G; Di Leonardo A
Eur J Med Chem; 2015 Aug; 101():236-44. PubMed ID: 26142488
[TBL] [Abstract][Full Text] [Related]
34. Identification of 14 novel mutations in the long isoform of USH2A in Spanish patients with Usher syndrome type II.
Aller E; Jaijo T; Beneyto M; Nájera C; Oltra S; Ayuso C; Baiget M; Carballo M; Antiñolo G; Valverde D; Moreno F; Vilela C; Collado D; Pérez-Garrigues H; Navea A; Millán JM
J Med Genet; 2006 Nov; 43(11):e55. PubMed ID: 17085681
[TBL] [Abstract][Full Text] [Related]
35. Pathogenesis and Treatment of Usher Syndrome Type IIA.
Zaw K; Carvalho LS; Aung-Htut MT; Fletcher S; Wilton SD; Chen FK; McLenachan S
Asia Pac J Ophthalmol (Phila); 2022 Jul-Aug 01; 11(4):369-379. PubMed ID: 36041150
[TBL] [Abstract][Full Text] [Related]
36. The effect of the common c.2299delG mutation in USH2A on RNA splicing.
Lenassi E; Saihan Z; Bitner-Glindzicz M; Webster AR
Exp Eye Res; 2014 May; 122():9-12. PubMed ID: 24607488
[TBL] [Abstract][Full Text] [Related]
37. Ataluren in cystic fibrosis: development, clinical studies and where are we now?
Zainal Abidin N; Haq IJ; Gardner AI; Brodlie M
Expert Opin Pharmacother; 2017 Sep; 18(13):1363-1371. PubMed ID: 28730885
[TBL] [Abstract][Full Text] [Related]
38. A combination of two truncating mutations in USH2A causes more severe and progressive hearing impairment in Usher syndrome type IIa.
Hartel BP; Löfgren M; Huygen PL; Guchelaar I; Lo-A-Njoe Kort N; Sadeghi AM; van Wijk E; Tranebjærg L; Kremer H; Kimberling WJ; Cremers CW; Möller C; Pennings RJ
Hear Res; 2016 Sep; 339():60-8. PubMed ID: 27318125
[TBL] [Abstract][Full Text] [Related]
39. Ataluren suppresses a premature termination codon in an MPS I-H mouse.
Wang D; Xue X; Gunn G; Du M; Siddiqui A; Weetall M; Keeling KM
J Mol Med (Berl); 2022 Aug; 100(8):1223-1235. PubMed ID: 35857082
[TBL] [Abstract][Full Text] [Related]
40. Aminoglycoside drugs induce efficient read-through of
Fazzari M; Frasca A; Bifari F; Landsberger N
RNA Biol; 2019 Oct; 16(10):1414-1423. PubMed ID: 31232219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
